Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Cash (2016 - 2025)

Historic Change in Cash for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to -$346.8 million.

  • Ptc Therapeutics' Change in Cash fell 16933.1% to -$346.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.5 million, marking a year-over-year decrease of 5911.88%. This contributed to the annual value of $185.0 million for FY2024, which is 4113.99% down from last year.
  • Per Ptc Therapeutics' latest filing, its Change in Cash stood at -$346.8 million for Q3 2025, which was down 16933.1% from -$462.8 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Change in Cash registered a high of $700.5 million during Q1 2025, and its lowest value of -$462.8 million during Q2 2025.
  • For the 5-year period, Ptc Therapeutics' Change in Cash averaged around $24.7 million, with its median value being -$9.1 million (2023).
  • Per our database at Business Quant, Ptc Therapeutics' Change in Cash skyrocketed by 17551400.0% in 2022 and then crashed by 54534.01% in 2025.
  • Ptc Therapeutics' Change in Cash (Quarter) stood at -$100000.0 in 2021, then soared by 175514.0% to $175.4 million in 2022, then skyrocketed by 144.49% to $428.9 million in 2023, then plummeted by 40.42% to $255.5 million in 2024, then plummeted by 235.71% to -$346.8 million in 2025.
  • Its Change in Cash was -$346.8 million in Q3 2025, compared to -$462.8 million in Q2 2025 and $700.5 million in Q1 2025.